Implantica schedules Q3 2026 briefing for 19 November

Implantica has announced an investor presentation for its third-quarter 2026 report on 19 November at 15:00 CET, with the interim report scheduled for publication at 08:00 CET that day.

In a company release distributed through PR Newswire, the medtech business said the presentation would be conducted in English via webcast and teleconference. The announcement lists chief executive Peter Forsell, chief financial officer Andreas Öhrnberg and chief corporate affairs officer Nicole Pehrsson as speakers.

Investors can access the webcast through the event link supplied by Implantica. Teleconference participants must register separately to receive a telephone number and conference ID. The release does not include quarterly financial figures or indicate what operational developments management will discuss.

Implantica describes its business as developing implantable technologies intended to improve patient outcomes and quality of life. Its lead product, RefluxStop, is an implant for treating gastroesophageal reflux disease, or GERD.

The company says RefluxStop is approved by the US Food and Drug Administration and carries CE marking. It also claims strong long-term clinical outcomes. Those statements are company claims: the supplied announcement does not include regulatory documents or clinical data supporting them.

Beyond RefluxStop, Implantica says its product pipeline partly incorporates two technology platforms. An eHealth platform is designed to support communication with, and remote monitoring and control of, implants inside the body. A wireless power platform is intended to supply energy to implantable devices through intact skin.

The release describes these devices as investigational and says they are intended to enable remote treatment changes. It provides no timetable for their availability. Implantica is listed on Stockholm’s Nasdaq First North Premier Growth Market under the ticker IMP A SDB, with FNCA Sweden AB named as its Certified Adviser.